This author has not written his bio yet.
But we are proud to say that Etira contributed 37 entries already.
San Antonio, TX – October 15, 2026 Adriana Baker, a MD PhD candidate in the laboratory of EtiraRx founder Dr. Ratna Vadlamudi at UT Health San Antonio, presented exciting new findings at the 2026 San Antonio Liver Cancer Symposium, held October 8–9. Her presentation, “ERX-315 Creates Metabolic Stress Vulnerability to DNA Damaging Therapy in HCC,” demonstrated […]
San Antonio, TX – October 12, 2026 We are pleased to share our new paper in Cancer Research Communications, showing that ERX-208, Etira’s LIPA-targeting compound, disrupts DNA repair in ovarian cancer cells by inducing sustained endoplasmic reticulum (ER) stress. Cancers with homologous recombination deficiency (HRD), such as those carrying BRCA mutations, are particularly sensitive to […]
Dallas, Texas — September 7, 2026 Etira today announced that a patient enrolled in its ongoing Phase 1 clinical trial of ERX-315 (NCT06533332) has now remained on treatment for more than one year. The patient entered the ERX-315-101 study with advanced cancer that had progressed on prior systemic therapies. Treatment of this duration is notable […]
San Diego, CA – April 20, 2026. Durga Paneerdoss, an undergraduate working in the laboratory of EtiraRx founder Ratna Vadlamudi received the Third Place Prize in the Margaret Foti Foundation Undergraduate Student Prize competition at the AACR Undergraduate Student Caucus and Poster Competition during the American Association for Cancer Research Annual Meeting 2026 in San […]
Dallas, TX – April 14, 2026 We are pleased to announce that EtiraRx has been selected for the 2025 MassChallenge U.S. Early Stage Healthcare Cohort — a highly selective, zero-equity accelerator! This puts us alongside a global network of high-impact startups and gives us access to world-class mentors, investors, and healthcare leaders as we advance […]
San Antonio, TX – March 23, 2026. We are pleased to present our new open-access paper in Biomolecules (link here). Our paper shows activity of ERX-41 in Inflammatory breast cancer (IBC), a rare (2–4%) extremely aggressive subset of breast cancer, marked by rapid onset, early metastasis, and dismal 5-year survival (~40%) despite multimodal therapy. Key […]
San Antonio TX, February 06, 2026 Introducing ERX-208 – our supercharged ERX-41 analog for ovarian cancer! Publication in Oncogene shows the same powerful MOA of inducing uncompensated ER stress, but ERX-208 delivers dramatically higher potency by engaging LIPA across a vastly larger interaction surface. Link to paper; https://lnkd.in/eJ2EJDRd
Congratulations to Dr Annalisa Jenkins OBE, a member of Etira’s Board of Directors, who has been appointed an Officer of the Order of the British Empire (OBE) in The King’s New Year Honours for her contributions to the life sciences.
San Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio.
Dallas, Texas — June 26, 2025: Etira, a clinical-stage biopharmaceutical company aiming to develop cancer therapies, announced today that the first patient has been successfully treated at Dose Level Four (DL4) in its ongoing Phase 1 clinical trial of investigational drug ERX-315 (NCT06533332). ERX-315 is a first-in-class small-molecule therapy designed to induce endoplasmic reticulum (ER) […]
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247